Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia

被引：5
作者：
Yu, Nae [1 ]
Shin, Saeam [2 ]
Choi, Jong Rak [1 ]
Kim, Yoonjung [3 ]
Lee, Kyung-A [1 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Lab Med, 211 Eonju Ro, Seoul 06273, South Korea
[2] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Lab Med, Seoul, South Korea
[3] Yonsei Univ, Wonju Coll Med, Dept Lab Med, Wonju, South Korea
来源：
ANNALS OF LABORATORY MEDICINE | 2017年 / 37卷 / 02期
关键词：
BLAST-CRISIS; GENOMIC INSTABILITY; CELLS; MUTATOR; CML;
D O I：
10.3343/alm.2017.37.2.177
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：177 / 179
页数：3
相关论文
共 32 条
  • [31] Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
    Theresa Klümper
    Henrike Bruckmueller
    Tobias Diewock
    Meike Kaehler
    Sierk Haenisch
    Christiane Pott
    Oliver Bruhn
    Ingolf Cascorbi
    Experimental Hematology & Oncology, 9
  • [32] Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the AblT315I mutant kinase to combat imatinib resistance in chronic myeloid leukemia
    Al Shahrani, Mesfer
    Gahtani, Reem M.
    Abohassan, Mohammad
    Alasmari, Sultan
    Makkawi, Mohammed
    MEDICAL ONCOLOGY, 2023, 40 (11)
1234